2:01 PM
 | 
Oct 23, 2017
 |  BC Extra  |  Clinical News

Replicor HBV combo leads to functional control

2:01 PM
Oct 23, 2017
by Jaime De Leon
Text Size A A A
Print Print
PDF PDF

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir disoproxil fumarate and Pegasys peginterferon alfa-2a led to functional disease control in eight of 10 patients. Replicor CSO Andrew Vaillant told BioCentury the company plans to start a U.S. Phase II trial of the combination next year.

The open-label trial...

Read the full 345 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra
Sign Up

Article Purchase

$35 USD
More Info >